Ningxia Zhongke Biotechnology Co., Ltd. Class A

Ningxia Zhongke Biotechnology Co., Ltd. Class A

SSSE:600165
2.46
CNY
-0.07
(-2.77%)
-0.05EPS
5.41BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A carries a market capitalization of 5.41B, placing it among publicly traded companies globally. Its enterprise value stands at 5.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.41B
Enterprise Value5.46B

Share Statistics

As of September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A has 1.62B shares outstanding.

Shares Outstanding1.62B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 10.24, and the price-to-book ratio stands at 5.32.

PS Ratio10.24
PB Ratio5.32
P/TBV Ratio5.65

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 10.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.46B versus a market cap of 5.41B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales10.34

Financial Position

As of September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A maintains a current ratio of 1.96, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.43, indicating moderate leverage, while an interest coverage ratio of -2.31 demonstrates limited ability to service its debt obligations.

Current Ratio1.96
Quick Ratio0.34
Debt / Equity1.43
Debt / EBITDA-0.27
Interest Coverage-2.31

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -1.32, reflecting losses generated across the asset base. The company generates approximately 584,005.74 in revenue per employee across its workforce of 904.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.14 indicates how many times Ningxia Zhongke Biotechnology Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-1.32
Revenue Per Employee584,005.74
Employee Count904.00
Inventory Turnover3.14

Taxes

CNY

Over the twelve months ended September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A recorded 4.86M in income tax expense. The company reported a pretax loss of -68.57M and -30.40M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax4.86M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A's stock has declined approximately 40.00% over the past 52 weeks. The 50-day moving average sits at 3.04, while the 200-day moving average is 3.14.

52-Week Price Change-40.00%
50-Day Moving Average3.04
200-Day Moving Average3.14

Income Statement

CNY

Over the twelve months ended September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A generated 527.94M in revenue and converted that into -30.40M in net income, yielding earnings per share of -0.05. EBITDA reached -61.81M, while operating income came in at -140.43M.

Revenue527.94M
Gross Profit-34.36M
Operating Income-140.43M
Pretax Income-68.57M
Net Income-30.40M
EBITDA-61.81M
EBIT-61.81M
Earnings Per Share (EPS)-0.05

Balance Sheet

CNY

As of September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A holds 95.63M in cash and equivalents against 16.39M in total debt, resulting in a net debt position of -85.63M. Total book value stands at 1.02B, with working capital of 268.35M providing operational flexibility.

Cash & Cash Equivalents95.63M
Total Debt16.39M
Net Debt-85.63M
Equity (Book Value)1.02B
Book Value Per Share0.63
Working Capital268.35M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-287.94M

Margins

Over the twelve months ended September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A posted a gross margin of -6.51, reflecting its pricing power and cost economics. The operating margin of -26.60 and net profit margin of -5.76 provide insight into operational efficiency.

Gross Margin-6.51
Operating Margin-26.60
Pretax Margin-12.99
Profit Margin-5.76
EBITDA Margin-11.71

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of -8.96 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -14.67, meaning Ningxia Zhongke Biotechnology Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.01
Payout Ratio-8.96
Shareholder Yield-14.67

Stock Splits

Ningxia Zhongke Biotechnology Co., Ltd. Class A's most recent stock split took place on October 12, 2015 with a 2:5 split ratio.

Last Split Date10/12/2015
Split Ratio2:5

Scores

As of September 30, 2026, Ningxia Zhongke Biotechnology Co., Ltd. Class A has an Altman Z-Score of 1.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.80